Immuron Limited (NASDAQ:IMRN) suffered a 25.8% drop in shares after announcing a failed clinical trial for an ETEC hyperimmune bovine colostrum product. The study, conducted by the Uniformed Services University, aimed to evaluate gut health maintenance during travel and deployment. IMRN clarified that the product tested was not Travelan.

The FDA approved Immuron Limited (NASDAQ:IMRN)’s IMM-529 drug for a phase 2 clinical trial to treat Clostridioides difficile infection. The study is set to begin in the first half of 2026, enrolling up to 60 participants suffering from the disease. IMRN’s potential as an investment is noted, but some AI stocks may offer higher returns.

Bloom Energy (BE) saw a 23% surge in shares due to new supply deals. IMRN’s recent developments in clinical trials and potential as an investment are noted, while highlighting other AI stocks that may offer higher returns. For more information on promising stocks, check out our reports on stocks that may double in three years and hidden AI stocks to buy now.

Read more at Yahoo Finance: Immuron (IMRN) Struggles After Announcing Trial Results